Baseline genetic abnormalities and effectiveness of osimertinib treatment in patients with chemotherapy-naïve EGFR-mutated NSCLC based on performance status by Yoshihiko Taniguchi, Akihiro Tamiya, Mitsuo Osuga, Daijiro Harada, Shun-ichi Isa, Keiichi Nakamura, Yasuyuki Mizumori, Tsutomu Shinohara, Hidetoshi Yanai, Katsumi Nakatomi, Masahide Oki, Masahide Mori, Tomohito Kuwako, Koji Yamazaki, Atsuhisa Tamura, Masahiko Ando, Yasuhiro Koh

Get full text

Real‐world first‐line treatment with pembrolizumab for non‐small cell lung carcinoma with high PD‐L1 expression: Updated analysis by Yasuyuki Ikezawa, Ryo Morita, Hidenori Mizugaki, Kazunari Tateishi, Keiki Yokoo, Toshiyuki Sumi, Hajime Kikuchi, Yasuo Kitamura, Atsushi Nakamura, Maki Kobayashi, Mari Aso, Nozomu Kimura, Fumiaki Yoshiike, Furuta Megumi, Hisashi Tanaka, Motoki Sekikawa, Tsutomu Hachiya, Keiichi Nakamura, Fumihiro Hommura, Noriaki Sukoh, Kenichiro Ito, Takashi Kikuchi, Toshihiko Agatsuma, Hiroshi Yokouchi

Get full text

Real‐world data on the efficacy and safety of immune‐checkpoint inhibitors in elderly patients with non‐small cell lung cancer by Daisuke Morinaga, Hajime Asahina, Shotaro Ito, Osamu Honjo, Hisashi Tanaka, Ryoichi Honda, Hiroshi Yokouchi, Keiichi Nakamura, Kei Takamura, Fumihiro Hommura, Yasutaka Kawai, Kenichiro Ito, Noriaki Sukoh, Keiki Yokoo, Ryo Morita, Toshiyuki Harada, Taichi Takashina, Tomohiro Goda, Hirotoshi Dosaka‐Akita, Hiroshi Isobe, the Hokkaido Lung Cancer Clinical Study Group Trial

Get full text